SAFE vs Convertible Notes: What Happens When You Choose Wrong

# SAFE vs Convertible Notes: What Happens When You Choose Wrong

We've watched hundreds of founders sign either a SAFE note or convertible note without understanding one critical fact: **the choice doesn't just affect paperwork—it fundamentally changes how much equity you'll give away and when.**

Most founders pick whichever instrument their lead investor prefers. SAFEs feel "friendlier" because they're simpler. Convertible notes feel "traditional" because banks have used them forever. Neither reason actually matters.

What matters is the mechanics underneath. And those mechanics cost you thousands—sometimes hundreds of thousands—of dollars in dilution by the time you raise Series A.

Let's talk about what actually happens when you sign each one, and how to structure your deal so you don't regret it.

## The Real Difference: Timing of Dilution

Here's what most articles won't tell you: **the choice between SAFE notes and convertible notes is really about *when* dilution happens, not *if* it happens.**

With a convertible note, dilution is built into the instrument from day one:
- You're signing a debt instrument with interest accruing
- The investor is earning a return (usually 5-10% annually) whether you hit milestones or not
- When you raise Series A, that accrued interest converts to equity at a discount
- You're paying for money you borrowed 18 months ago by giving up more equity today

With a SAFE note, dilution is deferred:
- No interest accrues (though some SAFEs include interest—more on that later)
- The investor has no claim until a qualifying event (Series A funding, acquisition, dissolution)
- When that event happens, the conversion happens instantly
- The math is simpler, but the outcome can be just as expensive

We worked with a Series B fintech company last year that discovered they'd issued $800K in convertible notes at 8% annual interest during their seed round. The notes had been outstanding for 20 months. By the time Series A closed, that $800K had accrued $106K in additional equity obligation.

They didn't negotiate the interest rate. They just accepted what was standard.

Standard is expensive.

## The Cost Mechanics Investors Don't Explain

### Convertible Note Math

Let's use a real example. You raise $500K on a convertible note with:
- 5% annual interest
- $5M valuation cap (the highest valuation at which the note converts)
- 20% discount (you convert at 20% off the Series A price)

Eighteen months later, your Series A is $10M.

Here's what actually happens:

**The note investor gets the better of two paths:**

1. **Discount path**: Series A price is $10/share. The investor converts at $8/share (20% discount).
2. **Cap path**: The valuation cap implies a $5M value. If the note size is $500K, that's 10% of a $5M company. But wait—18 months of 5% interest is $45K. Total obligation: $545K on a $10M Series A = 5.45% dilution.

They take whichever gives them more shares. In this case, the discount is better for them. But you've also paid that interest whether they use it or not.

Now multiply this across 3-5 seed investors, and your Series A dilution compounds.

### SAFE Note Math

SAFE notes work differently. Same scenario: $500K SAFE with $5M cap and 20% discount.

At Series A ($10M valution):
- **MFN (Most Favored Nation) clause**: If any other SAFE holder negotiated better terms, this investor gets those terms automatically
- **Pro-rata rights**: Often included, letting the investor participate in Series A to maintain ownership percentage
- **Valuation cap**: Still applies, still creates the same dilution

The difference: **no interest accruing**. That's $45K in dilution you avoided.

But here's what trips up founders: many SAFEs now include interest (called "post-money" or "interest" SAFEs). If you've signed one with interest, you're paying nearly the same cost as a convertible note—without the protective features convertible notes provide.

We audited a Series B SaaS company's cap table and found they'd issued four SAFEs with interest at 5%. They thought they were simpler than convertible notes. They weren't. They'd just negotiated worse terms.

## What Investors Don't Want You to Know About MFN Clauses

This is where it gets interesting.

Most SAFEs include an MFN clause. On the surface, it sounds protective: if you negotiate better terms with one investor, all other SAFE holders automatically get those terms.

But investors know how to work around this.

Here's what we've seen happen:

**Round 1**: You raise from three seed investors. All three SAFEs have identical $5M caps and MFN clauses.

**Series A prep**: You realize one investor got better terms. By the time you discover it, the Series A is closing in two weeks. You don't have time to renegotiate three SAFEs.

Instead of fighting, you accept that all three MFN clauses trigger, and your Series A dilution increases by 2-3% more than you budgeted.

This isn't theoretical. We've seen founders lose 4-5% of their company to unexpected MFN triggers because they signed SAFEs without understanding the clause.

**The real problem**: MFN clauses are good for *investors*, not you. They're good when you're the investor protecting downside. They're bad when you're the founder managing dilution.

Some Series A investors now refuse to lead rounds if SAFEs have MFN clauses with other investors. They want cleaner cap tables. But by then, you've already signed them.

## Convertible Notes: The Protection You're Not Using

Here's something most articles miss: **convertible notes actually give you more protection than SAFEs**, but founders ignore it because they focus on simplicity.

Convertible notes have:

**Maturity dates**: The note must be paid back (or convert) by a specific date. This forces action. If you haven't raised Series A by maturity, you owe the money back or negotiate extension terms. This pressure can be good—it prevents perpetual seed limbo.

**Interest rate as leverage**: The interest rate is negotiable. We've negotiated 2% notes before (vs. the standard 5-8%). Over 18 months, that's the difference between $45K and $18K in dilution. But you have to ask.

**Defined conversion events**: Only Series A (or similar qualified rounds) trigger conversion. SAFEs sometimes have broader definitions (like revenue milestones), which can trigger unexpected dilution.

We worked with a Series A healthcare company that had signed a SAFE with a $1M revenue trigger. When they hit $950K in ARR, investors started pushing to close their Series A early. They wanted to convert before the company hit that revenue number.

The founder didn't realize the SAFE had a revenue trigger until investors mentioned it. They'd signed without reading the fine print.

With a convertible note, that kind of ambiguity would have been explicit from the start.

## The Cap Table Decisions That Matter

When we help founders prepare for Series A, one of the first things we do is model cap table scenarios. Here's what we always find:

**Scenario 1: Three convertible notes ($1.5M total) at 6% over 18 months**
- Interest accrued: ~$135K
- Total dilution at $10M Series A: 16-18% (depending on caps)
- Founder equity: ~75%

**Scenario 2: Three SAFEs ($1.5M total) with $5M caps, no interest**
- Dilution at $10M Series A: 13-15%
- Founder equity: ~77%

**Scenario 3: Three SAFEs ($1.5M total) with $5M caps AND interest**
- Interest accrued: ~$135K
- Total dilution: 16-18%
- Founder equity: ~75%

Scenario 3 is what most founders end up with. They thought they were choosing SAFEs. They just negotiated them like convertible notes.

## The Negotiation Checklist Most Founders Skip

When you're pitching seed investors, you're not thinking about cap table optimization. You're thinking about closing the round.

Then you get the term sheet for your SAFE or convertible note, and you're exhausted. So you sign.

Don't do that. Here's what to negotiate:

### For Convertible Notes:

- **Interest rate**: Push for 3-4% instead of 5-8%. This is always negotiable.
- **Maturity period**: Longer is better for you (gives you more time to raise Series A without extending)
- **Valuation cap**: This is hard to negotiate, but worth trying. Higher caps = less dilution for you.
- **Discount rate**: Negotiate 15% instead of 20%. Half a percent is real money on a $5M cap table.
- **Investor pro-rata rights**: Limit them. Not every seed investor should have a right to participate in Series A.

### For SAFEs:

- **Avoid interest**: If possible, sign post-money SAFEs without interest. If not, push hard on interest rates.
- **Limit MFN clauses**: Negotiate that MFN clauses only apply within the seed round, not across all time.
- **Define triggering events clearly**: Make sure Series A is the only triggering event. No revenue triggers, no arbitrary conditions.
- **Valuation cap**: Same as convertible notes—push it higher.
- **Pro-rata scope**: Specify exactly which rounds trigger pro-rata rights.

**Real numbers**: We negotiated a SAFE for a Series B marketplace company. The investor's initial term sheet included a 4% interest provision and MFN clause. We removed the interest (arguing for post-money SAFE) and narrowed the MFN clause to only apply within their seed cohort.

That change alone saved them ~$60K in dilution by Series A.

## When to Use Each One

After all this, here's when each instrument actually makes sense:

**Use convertible notes if:**
- You want clear exit pressure (maturity date forces Series A closure)
- You have early-stage investors who understand debt instruments
- You're comfortable negotiating interest rates and discounts
- You want explicit conversion mechanics

**Use SAFEs if:**
- Your lead investor insists on SAFEs (and they're a strong lead)
- You want the simplest possible document
- You can negotiate away interest and MFN clauses
- You're confident you'll raise Series A within 18-24 months

**Use neither if:**
- You can raise a pre-Series A round at a real valuation
- You have strong revenue traction (often you can skip seed entirely)

We've seen founders skip SAFEs and convertible notes entirely by raising a small Series A at $2-3M instead of doing a $500K seed round. Fewer documents, cleaner cap table, less dilution.

But that's only possible if you have the traction and the connections to go straight to institutional investors.

## The Series A Surprise You Can Avoid

Last year, we worked with a Series A-stage fintech company whose cap table was a mess. They'd raised $2M in seed from eight different investors using a mix of convertible notes and SAFEs. Three of the convertible notes hadn't been on consistent terms. Two SAFEs had different MFN clause interpretations.

When Series A closed, the cap table reconciliation took three weeks. One seed investor claimed they had pro-rata rights that nobody else had. Another investor's SAFE had an ambiguous trigger language that nobody could parse.

The company's Series A investors almost walked away because the cap table was so confusing.

This didn't need to happen. The founder had just signed documents without coordinating terms across investors.

When we prepare [Series A (/blog/series-a-preparation-the-hidden-financial-leverage-most-founders-miss/), we always audit existing SAFEs and convertible notes. We've caught errors that cost founders tens of thousands to fix.

## What Actually Matters for Your Decision

Here's the bottom line: **the choice between SAFE and convertible note matters less than the specific terms you negotiate.**

A poorly negotiated SAFE costs more than a well-negotiated convertible note.

A convertible note with 8% interest and 20% discount costs significantly more than a SAFE with no interest and higher caps.

Most founders focus on the wrong thing. They ask, "Which is simpler?" They should ask, "Which terms can I actually negotiate?"

The answer is almost always: more than you think.

But you have to ask. And you have to understand what each term actually costs you.

---

## Ready to Optimize Your Cap Table?

If you're evaluating SAFE notes or convertible notes, or if you're already in a seed round and want to make sure your terms are competitive, **Inflection CFO offers a free financial audit** that includes cap table analysis and seed round term review.

We'll show you exactly what your SAFE or convertible note is costing you, spot negotiation opportunities you've missed, and help you structure your deal so Series A doesn't become a dilution surprise.

[Schedule your free consultation](/contact) and let's make sure you understand every term you're signing.